Show simple item record

dc.contributor.authorRobbrecht, D. G. J.
dc.contributor.authorLopez, J.
dc.contributor.authorCalvo, E.
dc.contributor.authorHe, X.
dc.contributor.authorHiroshi, H.
dc.contributor.authorSoni, N.
dc.contributor.authorCook, Natalie
dc.contributor.authorDowlati, A.
dc.contributor.authorFasolo, A.
dc.contributor.authorMoreno, V.
dc.contributor.authorEskens, F.
dc.contributor.authorde Bono, J. S.
dc.date.accessioned2020-11-16T07:49:15Z
dc.date.available2020-11-16T07:49:15Z
dc.date.issued2020en
dc.identifier.citationRobbrecht DGJ, Lopez J, Calvo E, He X, Hiroshi H, Soni N, et al. A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. Br J Cancer. 2020.en
dc.identifier.pmid33020594en
dc.identifier.doi10.1038/s41416-020-01100-3en
dc.identifier.urihttp://hdl.handle.net/10541/623428
dc.description.abstractBackground: This is a first-in-human study with TAS-119, an Aurora A kinase (AurA) inhibitor. Methods: Patients with advanced, refractory, solid tumours were enrolled into 5 dose escalation cohorts (70-300 mg BID, 4 days on/3 days off, 3 out of 4 weeks or 4 out of 4 weeks). The expansion part consisted of patients with small-cell lung cancer, HER2-negative breast cancer, MYC-amplified/?-catenin-mutated (MT) tumours or other (basket cohort). Results: In the escalation part (n = 34 patients), dose-limiting toxicities were one grade 3 nausea, two grade 2 and one grade 3 ocular toxicity and a combination of fatigue, ocular toxicity and nausea in one patient (all grade 2) at dose levels of 150, 200, 250 and 300 mg, respectively. Most frequent treatment-related adverse events were fatigue (32%), diarrhoea (24%) and ocular toxicity (24%). Toxicity grade ?3 in ?10% of patients were diarrhoea (15%) and increased lipase (12%). The maximum tolerated dose was 250 mg BID. Due to one additional grade 1 ocular toxicity, the RP2D was set at 200 mg BID (4 days on/3 days off, 3 out of 4 weeks), which was further explored in the expansion part (n = 40 patients). Target inhibition in paired skin biopsies was shown. Conclusions: TAS-119 has a favourable and remarkably distinct safety profile from other AurA inhibitors.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-020-01100-3en
dc.titleA first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursen
dc.typeArticleen
dc.contributor.departmentErasmus MC Cancer Institute, Rotterdam, the Netherlands.en
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record